



ARO A BIOSURGERY QUARTERLY RESULTS WEBINAR - CORRECTION

Soft tissue regeneration company Aroa Biosurgery Limited (ASX: ARX, 'ARO A' or the 'Company') hereby corrects the announcement issued earlier today titled "Notification of Quarterly Results Webinar". The initial announcement mistakenly referred to the December Quarterly Results. However, please note that the webinar will focus on the March 2024 Quarterly Results.

All other details and content of the initial announcement remain unchanged. Please refer attached corrected announcement for your reference.

Authorised on behalf of the Aroa Biosurgery Board of Directors by Brian Ward, CEO.

About Aroa Biosurgery:

Aroa Biosurgery is a soft-tissue regeneration company committed to 'unlocking regenerative healing for everybody'. We develop, manufacture, sell and distribute medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Our products are developed from a proprietary ARO A ECM™ technology platform, a novel extracellular matrix biomaterial derived from ovine (sheep) forestomach. Over 6 million ARO A products have been used globally in a range of procedures to date, with distribution into our key market of the United States via our direct sales force and our partner TELA Bio, Inc. Founded in 2008, ARO A is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX: ARX). www.aroabio.com

Contacts

investor@aroabio.com
+ 64 21 744 915



AROA BIOSURGERY QUARTERLY RESULTS WEBINAR

Soft tissue regeneration company Aroa Biosurgery Limited (ASX: ARX, 'AROA' or the 'Company') is pleased to announce it will hold a webinar with CEO Brian Ward and CFO James Agnew on **Tuesday 30 April 2024, at 9 AM AEST**, to discuss the March Quarterly Results.

Investors and interested parties can register to attend the webinar via the following link:

https://us02web.zoom.us/webinar/register/WN_mxRKF5uWRW6co21L8tUa7Q

Questions can be submitted before the webinar to investor@aroabio.com or during the webinar using the Q&A function on Zoom.

Authorised on behalf of the Aroa Biosurgery Board of Directors by Brian Ward, CEO.

About Aroa Biosurgery:

Aroa Biosurgery is a soft-tissue regeneration company committed to 'unlocking regenerative healing for everybody'. We develop, manufacture, sell and distribute medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Our products are developed from a proprietary AROA ECM™ technology platform, a novel extracellular matrix biomaterial derived from ovine (sheep) forestomach. Over 6 million AROA products have been used globally in a range of procedures to date, with distribution into our key market of the United States via our direct sales force and our partner TELA Bio, Inc. Founded in 2008, AROA is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX: ARX). www.aroabio.com

Contacts

investor@aroabio.com

+ 64 21 744 915